

# Phathom<sup>®</sup>

## PHARMACEUTICALS

### Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

September 5, 2023

FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:

- **Morgan Stanley 21<sup>st</sup> Annual Global Healthcare Conference** in New York City. Management will participate in one-on-one meetings on September 12, 2023.
- **H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference** in New York City. Management will participate in a fireside chat on Wednesday, September 13, 2023 at 2:30 p.m. EDT and one-on-one meetings throughout the day.

To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. The recording will be available for 90 days following the event.

#### **About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow the Company on [LinkedIn](#) and [Twitter](#).

#### **MEDIA CONTACT**

Nick Benedetto  
1-877-742-8466  
[media@phathompharma.com](mailto:media@phathompharma.com)

#### **INVESTOR CONTACT**

Eric Sciorilli  
1-877-742-8466  
[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2023 Phathom Pharmaceuticals. All rights reserved.